Inclusion Criteria:

        Participants must satisfy the following criteria to be enrolled in the study:

          -  Participant has documented diagnosis of MM and measurable disease, defined as:

               1. M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis
                  [uPEP]): sPEP ≥ 0.5 g/dL or uPEP ≥ 200 mg/24 hours and/or

               2. Light chain MM without measurable disease in the serum or urine: Serum
                  immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum
                  immunoglobulin kappa lambda free light chain ratio

          -  Participant has received:

               1. at least 3 prior MM regimens for Arm A Cohort 1 and Arm B

               2. at least 1 but no greater than 3 prior MM regimens for Arm A Cohort 2 and Arm C.

          -  Arm A Cohort 1 and Arm B: Participant has received prior treatment with an
             immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody-containing
             regimen for at least 2 consecutive cycles.

          -  Arm A Cohort 2 and Arm C: Participant has received prior treatment with an
             immunomodulatory agent for at least 2 consecutive cycles.

          -  Evidence of PD during or within 6 months (measured from the last dose of any drug
             within the regimen) of completing treatment with the last antimyeloma regimen before
             study entry.

          -  Participant achieved a response (minimal response [MR] or better) to at least 1 prior
             treatment regimen.

          -  Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
             or 1.

        Exclusion Criteria:

        The presence of any of the following will exclude a participant from enrollment:

          -  Participant has non-secretory MM or has history of or active plasma cell leukemia,
             Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly,
             endocrinopathy, monoclonal protein, and skin changes) or amyloidosis.

          -  Participant has any of the following laboratory abnormalities:

               1. ANC and Platelets count as reported below

               2. Hemoglobin < 8 g/dL (< 4.9 mmol/L) (transfusion is not permitted within 21 days
                  of screening)

               3. Creatinine clearance (CrCl) as reported below

               4. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L)

               5. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5
                  ×upper limit of normal (ULN)

               6. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for participants with documented
                  Gilbert's syndrome

               7. International normalized ratio (INR) or activated partial thromboplastin time
                  (aPTT) 1.5 × ULN, or history of Grade ≥ 2 hemorrhage within 30 days, or
                  participant requires ongoing treatment with chronic, therapeutic dosing of
                  anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors)

          -  Participant has inadequate pulmonary function defined as oxygen saturation (SaO2) <
             92% on room air.

          -  Participant has known chronic obstructive pulmonary disease (COPD) with a forced
             expiratory volume in 1 second (FEV1) 50% of predicted normal.

          -  Prior exposure to CC-220 (± low-dose dexamethasone) as part of their most recent
             antimyeloma treatment regimen (Arm A).

          -  Prior exposure to, BMS-986405 (JSMD194) (Arm B).

          -  Prior exposure to DARA in combination with POM with or without dexamethasone (DP±d) as
             part of their most recent antimyeloma treatment regimen (Arm C Cohort 1).

          -  Prior exposure to POM in combination with BTZ with or without dexamethasone (PV± d as
             part of their most recent antimyeloma treatment regimen (Arm C Cohort 2).

          -  Previous history of an allogeneic hematopoietic stem cell transplantation, treatment
             with any gene therapy-based therapeutic for cancer, investigational cellular therapy
             for cancer or BCMA targeted therapy.

          -  Treatment Arm A Cohort 1 and Arm B: participant has received autologous stem cell
             transplantation (ASCT) within 12 weeks prior to leukapheresis.

          -  Treatment Arms A Cohort 2 and Arm C: participant has received autologous stem cell
             transplantation (ASCT) within 12 months prior to leukapheresis.